Patient Gateway

RSS Feed

BBOT Reports BBO-8520 Data in NSCLC, Highlights Combination Results

“双恩”协同，精准破局--蒋晓东教授解读Endouble研究晚期NSCLC一线无化疗新路径探索_腾讯新闻

Risk-adaptive management of stage III NSCLC in the perioperative immunotherapy era: a critical synthesis and clinical framework

赵艳秋教授解读TOP研究：EGFR敏感突变（Ex19del/L858R）-TP53共突变晚期NSCLC一线治疗高级别循证证据公布_腾讯新闻

An exploratory case series of sequential stereotactic body radiotherapy and tislelizumab after platinum-doublet chemotherapy in stage IIIB/C–IV non-squamous NSCLC

Structural classification of EGFR mutations and its association with TKI efficacy against compound and co-mutations in a Chinese NSCLC cohort: a single-center retrospective analysis

David Ross: Exciting New Therapeutic Options for Stage 4A NSCLC in DREAM Study

Selecting Frontline Therapy for High-Risk EGFR-Mutated NSCLC

Akeso and Summit’s ivonescimab meets OS goals in NSCLC